Zacks.com on MSN6h
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Globus Medical (GMED) and Nevro Corp. (NVRO) have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, ...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is fair to Nevro shareholders.
Stifel analysts maintained a Buy rating and a $92.00 price target for Globus Medical (NYSE:GMED) stock following the company's announcement of acquiring Nevro Corp . (NYSE:NVRO) for an equity value of ...
Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...
Nevro (NVRO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...
Canaccord raised the firm’s price target on Nevro (NVRO) to $5.85 from $4 and keeps a Hold rating on the shares. The firm noted Globus Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback